Loading
Latest filing published 14 Jun 2023 for Oncternal Therapeutics, Inc., €8,125.
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Gunnar F. Kaufmann (senior executive) discloses dealings in Oncternal Therapeutics, Inc. to SEC (Form 4). Between 3 January 2022 and 14 June 2023, the trades on record add up to 5 filings.
Every open-market trade on record is a purchase: 2 purchases worth €9,120, and no sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 3 share grants. In 2023 alone, the filings show 2 purchases and no sales.
The record was last updated on 14 June 2023 with an open-market purchase (€995) in Oncternal Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. The legal deadline for a Form 4 is two business days after the transaction. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
4 of 4 declarations